These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12788413)

  • 21. The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review.
    Small W
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):68-74. PubMed ID: 11917288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amifostine: the first selective-target and broad-spectrum radioprotector.
    Kouvaris JR; Kouloulias VE; Vlahos LJ
    Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration.
    Werner-Wasik M; Langer C; Movsas B
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S105-8. PubMed ID: 16015544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Vikram B
    J Clin Oncol; 2001 Feb; 19(4):1233-4. PubMed ID: 11181692
    [No Abstract]   [Full Text] [Related]  

  • 27. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
    Sasse AD; Clark LG; Sasse EC; Clark OA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):784-91. PubMed ID: 16198504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amifostine: is there evidence of tumor protection?
    Koukourakis MI
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):18-30. PubMed ID: 14727237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
    Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Amifostine: current and future applications in cytoprotection].
    Lenoble M
    Bull Cancer; 1996 Sep; 83(9):773-87. PubMed ID: 8952658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.
    Chao KS; Ozyigit G; Thorsdad WL
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):101-8. PubMed ID: 14727250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential for use of amifostine in cervical cancer.
    Small W
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future development of amifostine as a radioprotectant.
    Werner-Wasik M
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine.
    McCumber LM
    Med Dosim; 2004; 29(2):139-43. PubMed ID: 15191764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
    Veerasarn V; Phromratanapongse P; Suntornpong N; Lorvidhaya V; Sukthomya V; Chitapanarux I; Tesavibul C; Swangsilpa T; Khorprasert C; Shotelersuk K; Kongthanarat Y; Panichevaluk A; Chiewvit S; Pusuwan P; Aekmahachai M; Ratchadara S; Sirilipoche S; Saengsuda Y
    J Med Assoc Thai; 2006 Dec; 89(12):2056-67. PubMed ID: 17214057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines for the administration of amifostine.
    Schuchter LM
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):40-3. PubMed ID: 8783665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
    Culy CR; Spencer CM
    Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.